Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To determine the impact of the restriction of the third and forth generation cephalosporins on the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a surgical intensive care unit (SICU)
Condition or disease
Gram-Positive Bacterial Infections
Drug: Piperacillin/tazobactam and other β-lactam/β-lactamase
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
All patients admitted to or transferred to the SICU.
Eligible patients will be patients of either sex, 18 years of age or older who are admitted or transferred to the SICU.
Provide written informed consent
Patients who have hypersensitivity to penicillin, cephalosporins or beta-lactamase inhibitors.
Females who are pregnant and breast feeding
Any underlying conditions or non-infectious diseases that will be ultimately fatal within 48 hours.
Those who have already been participating other clinical study related with antibiotics.